Luminol Composition for Post-COVID Sequelae Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective therapeutic options for the treatment of sequelae resulting from SARS-CoV-2 infections, which can cause long-lasting, debilitating symptoms in patients who have recovered from the acute phase of COVID-19.
Innovation Solution
The use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt, or its pharmaceutically acceptable salts, solvates, hydrates, crystalline polymorphs, tautomers, or isotopically enriched forms, to treat the sequelae of SARS-CoV-2 infection by targeting underlying inflammatory and oxidative stress pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (steroids, immunoglobulins, antivirals) are used for COVID-19 sequelae, then inflammatory response is suppressed, but treatment effectiveness is limited and side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of luminol to create new derivatives with optimized properties. Specifically, the patent introduces various substituent groups (R1-R6) at different positions of the luminol molecule to enhance its chemiluminescence stability and activity while reducing side effects. This structural parameter modification allows the compound to maintain therapeutic effectiveness while improving safety profile compared to conventional treatments.
Solution Approach 2:
The patent employs composite material principles by creating luminol derivatives that combine multiple functional groups within a single molecular structure. These compounds integrate the core luminol chemiluminescence capability with additional pharmacophoric groups that provide anti-inflammatory, antiviral, or immunomodulatory activities. This composite approach enables a single agent to address multiple pathological mechanisms of COVID-19 sequelae simultaneously, improving treatment reliability while potentially reducing the need for combination therapies that increase side effects.
2Reliability
If high doses of conventional medications are administered, then therapeutic effect is enhanced, but side effects and toxicity increase
Solution Approach 1:
The patent utilizes parameter changes by optimizing the chemical structure of luminol derivatives to achieve higher potency at lower doses. By introducing specific electron-donating or electron-withdrawing groups at strategic positions on the luminol ring system, the patent enhances the chemiluminescence quantum yield and stability, which correlates with improved biological activity. This allows therapeutic effects to be achieved at reduced dosages, thereby minimizing toxicity and side effects associated with high-dose conventional medications.
3Duration of action of stationary object
If prolonged treatment with conventional drugs is continued, then chronic inflammation is addressed, but patient quality of life deteriorates due to cumulative side effects
Solution Approach 1:
The patent applies parameter changes by designing luminol derivatives with improved pharmacokinetic properties, including enhanced metabolic stability and reduced clearance rates. The introduction of specific substituent groups modifies the compound's interaction with metabolic enzymes, extending its half-life and allowing for less frequent dosing. This extended duration of action enables prolonged treatment of chronic inflammation while maintaining patient quality of life through reduced dosing frequency and lower cumulative toxicity.
Solution Approach 2:
The patent incorporates self-service principles by designing luminol derivatives that activate through chemiluminescence reactions with endogenous peroxides in the body. This self-activating mechanism eliminates the need for external activation steps or complex dosing regimens, allowing the compound to automatically engage with pathological targets (such as NADPH oxidase in inflammatory cells) and produce therapeutic effects through light-emitting chemical reactions that occur naturally at the site of inflammation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces pro-inflammatory cytokines and oxidative stress, providing therapeutic benefits for a range of sequelae including chronic fatigue, respiratory issues, and neurological disorders, with potential for monotherapy or combination therapies.
Implementation Method 1
The invention relates to a new luminol and new uses thereof, in particular for the prophylaxis and the treatment of sequelae of a SARS-CoV-2 infection
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3E
AI summary
The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.